References

References

British national formulary (February 2013) [online; accessed 20 March 2013]

Donatucci CF, Brock GB, Goldfischer ER et al. (2011) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. British Journal of Urology International 107: 1110–6

Egerdie RB, Auerbach S, Roehrborn CG et al. (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. The Journal of Sexual Medicine 9: 271–81

Eli Lilly and Company Ltd (2012) Cialis summary of product characteristics [online; accessed 5 March 2013]

Gacci M, Corona G, Salvi M et al. (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology 61: 994–1003

HM Government (2004) NHS (General medical services contracts) (prescription of drugs etc.) regulations 2004 [online; accessed 5 March 2013]

National Institute for Health and Clinical Excellence (2010) Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97

National Clinical Guideline Centre (2010) Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97. London (UK): National Clinical Guideline Centre at The Royal College of Physicians

National Institute for Health and Clinical Excellence. Lower urinary tract symptoms in men. NICE Pathway [online; accessed 5 March 2013]

National Institute for Health and Clinical Excellence (2013) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal). NICE technology appraisal 273

Oelke M, Giuliano F, Mirone V et al. (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. European Urology 61: 917–25

Porst H, Kim ED, Casabe AR et al. (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. European Urology 60: 1105–13

Roehrborn CG, McVary KT, Elion-Mboussa A et al. (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. The Journal of Urology 180: 1228–34